HEATHER LUDVIGSEN

Heather Ludvigsen stands as a key figure at Novo Ventures, where she serves as a Partner, bringing a wealth of scientific knowledge and investment acumen to the firm. Novo Ventures is renowned for its strategic investments in the life sciences sector, aiming to support companies that are developing groundbreaking solutions in healthcare and biotechnology. As a Partner, Heather is instrumental in shaping the firm's investment strategy, particularly in identifying and evaluating early-stage opportunities with high growth potential.

Her investment focus at Novo Ventures centers on transformative companies within the life sciences, including biotechnology, pharmaceuticals, and medical devices. She is particularly adept at recognizing the scientific merit and commercial viability of novel therapeutic platforms, diagnostics, and other innovative healthcare technologies. Heather's work involves rigorous due diligence, engaging with scientific founders, and assessing market dynamics to ensure that Novo Ventures invests in companies poised for significant impact.

Heather's career background is uniquely suited to her role, combining deep scientific expertise with extensive investment experience. She holds a Ph.D. in Molecular Biology, providing her with a foundational understanding of the complex scientific principles underpinning many of Novo Ventures' portfolio companies. Prior to her current role, she gained valuable experience at Novo Seeds, the early-stage investment arm of Novo Holdings, where she honed her skills in identifying nascent opportunities and supporting their initial growth phases. Her tenure at Novo Holdings, the parent company, further broadened her perspective on global healthcare investment strategies.

At Novo Ventures, Heather is not only involved in capital allocation but also in providing strategic guidance and operational support to portfolio companies. She works closely with management teams, leveraging her network and insights to help these companies navigate critical development milestones, secure further funding, and ultimately bring their innovations to patients. While specific notable investments are often a collective effort within a firm, her contributions are vital in the identification and nurturing of promising early-stage biotech ventures that align with Novo Ventures' mission to advance global health. Her dedication to fostering scientific innovation underscores her commitment to making a tangible difference in the future of medicine.